Genomic splice-donor disruption rescues systemic disease in progeria

Abstract RNA splicing determines which protein isoforms a gene produces, and aberrant splice-site activation can cause severe disease 1,2 . In Hutchinson–Gilford progeria syndrome, a synonymous LMNA mutation strengthens a cryptic 5′ splice donor site to produce progerin, a toxic lamin A isoform driving premature cardiovascular death 3,4 . Within this cryptic donor, the activating mutation lies near the canonical GT dinucleotide required for splice-site recognition. A single guide can therefore preferentially pair with the mutant sequence while positioning Cas9 cleavage at this dinucleotide. Here we show that CRISPR/Cas9-mediated disruption of this splice site suppresses progerin without requiring precise correction of the activating mutation and prolongs lifespan in progeroid mice. In patient-derived fibroblasts and induced pluripotent stem cell-derived mesenchymal stem cells, this intervention reduced progerin by 92.7–96.8% while retaining lamin A and lamin C expression. A single neonatal injection of AAV9 carrying the corresponding mouse guide increased median survival from 115 to 279 days in Cas9-expressing Lmna G609G/G609G mice. Treatment attenuated aortic, skeletal and multiorgan pathology. Treated homozygous pairs produced 52 offspring across seven litters. These findings establish pathogenic splice signals as genomic targets for sustained suppression of toxic isoforms while retaining canonical gene output.